Cargando…

Determinants of resistance to VEGF-TKI and immune checkpoint inhibitors in metastatic renal cell carcinoma

Vascular endothelial growth factor tyrosine kinase inhibitors (VEGF-TKIs) have been the mainstay of treatment for patients with advanced renal cell carcinoma (RCC). Despite its early promising results in decreasing or delaying the progression of RCC in patients, VEGF-TKIs have provided modest benefi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharma, Revati, Kadife, Elif, Myers, Mark, Kannourakis, George, Prithviraj, Prashanth, Ahmed, Nuzhat
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8183071/ https://www.ncbi.nlm.nih.gov/pubmed/34099013 http://dx.doi.org/10.1186/s13046-021-01961-3

Ejemplares similares

Precision Medicine: An Optimal Approach to Patient Care in Renal Cell Carcinoma
por: Sharma, Revati, et al.
Publicado: (2022)

In Vitro and In Silico Analysis of Epithelial-Mesenchymal Transition and Cancer Stemness as Prognostic Markers of Clear Cell Renal Cell Carcinoma
por: Sharma, Revati, et al.
Publicado: (2023)

Paclitaxel-Induced Src Activation Is Inhibited by Dasatinib Treatment, Independently of Cancer Stem Cell Properties, in a Mouse Model of Ovarian Cancer
por: Kadife, Elif, et al.
Publicado: (2019)

Ovarian Cancer, Cancer Stem Cells and Current Treatment Strategies: A Potential Role of Magmas in the Current Treatment Methods
por: Ahmed, Nuzhat, et al.
Publicado: (2020)

Prognostic Role of Immune Checkpoint Regulators in Cholangiocarcinoma: A Pilot Study
por: Cao, Lu, et al.
Publicado: (2021)

TIMP-2 regulates proliferation, invasion and STAT3-mediated cancer stem cell-dependent chemoresistance in ovarian cancer cells
por: Escalona, Ruth M., et al.
Publicado: (2020)

Crosstalk between Immune Checkpoint Modulators, Metabolic Reprogramming and Cellular Plasticity in Triple-Negative Breast Cancer
por: Poddar, Arpita, et al.
Publicado: (2022)

Knock down of TIMP-2 by siRNA and CRISPR/Cas9 mediates diverse cellular reprogramming of metastasis and chemosensitivity in ovarian cancer
por: Escalona, Ruth M., et al.
Publicado: (2022)

Aberrant pregnancy-associated plasma protein-A expression in breast cancers prognosticates clinical outcomes
por: Prithviraj, Prashanth, et al.
Publicado: (2020)

Platinum-resistance in epithelial ovarian cancer: an interplay of epithelial–mesenchymal transition interlinked with reprogrammed metabolism
por: Leung, Dilys, et al.
Publicado: (2022)

The Many Facets of Metzincins and Their Endogenous Inhibitors: Perspectives on Ovarian Cancer Progression
por: Escalona, Ruth M., et al.
Publicado: (2018)

The attributes of plakins in cancer and disease: perspectives on ovarian cancer progression, chemoresistance and recurrence
por: Wesley, Tamsin, et al.
Publicado: (2021)

Expression of TIMPs and MMPs in Ovarian Tumors, Ascites, Ascites-Derived Cells, and Cancer Cell Lines: Characteristic Modulatory Response Before and After Chemotherapy Treatment
por: Escalona, Ruth M., et al.
Publicado: (2022)

Myocardial Infarction after Long-Term Treatment with a Tyrosine Kinase Inhibitor (TKI) with Anti-VEGF Receptor Activity
por: Paschke, L., et al.
Publicado: (2019)

Predictive Biomarkers for Immune Checkpoint Inhibitors in Metastatic Breast Cancer
por: Sivapiragasam, Abirami, et al.
Publicado: (2020)

Evaluation of tumor microenvironment and biomarkers of immune checkpoint inhibitor response in metastatic renal cell carcinoma
por: Brown, Landon C, et al.
Publicado: (2022)

Crosstalk between VEGFR and other receptor tyrosine kinases for TKI therapy of metastatic renal cell carcinoma
por: Lai, Yongchang, et al.
Publicado: (2018)

The efficacy of VEGFR TKI therapy after progression on immune combination therapy in metastatic renal cell carcinoma
por: Barata, Pedro Coelho, et al.
Publicado: (2018)

Momelotinib decreased cancer stem cell associated tumor burden and prolonged disease-free remission period in a mouse model of human ovarian cancer
por: Chan, Emily, et al.
Publicado: (2018)

Adding Cyclooxygenase Inhibitors to Immune Checkpoint Inhibitors Did Not Improve Outcomes in Metastatic Renal Cell Carcinoma
por: Zhang, Yumeng, et al.
Publicado: (2022)

Development of EGFR TKIs and Options to Manage Resistance of Third-Generation EGFR TKI Osimertinib: Conventional Ways and Immune Checkpoint Inhibitors
por: Wu, Leilei, et al.
Publicado: (2020)

Efficacy of immune checkpoint inhibitors in EGFR-Mutant NSCLC patients with EGFR-TKI resistance: A systematic review and meta-analysis
por: Qian, Xiaoyu, et al.
Publicado: (2022)

TKI or TKI combined with PD-1 inhibitors as second-line treatment for HCC patients after sorafenib failure
por: Lei, Jin, et al.
Publicado: (2022)

Determinants of Resistance to Checkpoint Inhibitors
por: Tran, Linda, et al.
Publicado: (2020)

Mediating EGFR-TKI Resistance by VEGF/VEGFR Autocrine Pathway in Non-Small Cell Lung Cancer
por: Osude, Chike, et al.
Publicado: (2022)

Outcome of immune checkpoint inhibitors in metastatic renal cell carcinoma across different treatment lines
por: Resch, I., et al.
Publicado: (2021)

Suspected immune checkpoint inhibitor‐induced pulmonary sarcoid reaction in metastatic renal cell carcinoma
por: Purcell, Victoria, et al.
Publicado: (2022)

Coalition of Oct4A and β1 integrins in facilitating metastasis in ovarian cancer
por: Samardzija, Chantel, et al.
Publicado: (2016)

Immune Checkpoint Inhibitors Plus Single-Agent Chemotherapy for Advanced Non-Small-Cell Lung Cancer After Resistance to EGFR-TKI
por: Deng, Haiyi, et al.
Publicado: (2021)

TKI safety
por: Hjorth-Hansen, Henrik
Publicado: (2019)

Combining checkpoint inhibitors and BRAF-targeted agents against metastatic melanoma
por: Cooper, Zachary A., et al.
Publicado: (2013)

Monitoring Immune Checkpoint Regulators as Predictive Biomarkers in Hepatocellular Carcinoma
por: Shrestha, Ritu, et al.
Publicado: (2018)

Evaluation of response from axitinib per Response Evaluation Criteria in Solid Tumors versus Choi criteria in previously treated patients with metastatic renal cell carcinoma
por: Karakiewicz, Pierre I, et al.
Publicado: (2016)

Unique proteome signature of post-chemotherapy ovarian cancer ascites-derived tumor cells
por: Ahmed, Nuzhat, et al.
Publicado: (2016)

Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors
por: Nuzzo, Pier Vitale, et al.
Publicado: (2020)

Novel Risk Scoring System for Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
por: Martini, Dylan J., et al.
Publicado: (2019)

A case of sarcoidosis‐like reaction associated with immune checkpoint inhibitors in metastatic renal cell carcinoma
por: Katagiri, Akiyoshi, et al.
Publicado: (2021)

Metastatic Clear-Cell Renal Cell Carcinoma in the Era of Immune Checkpoint Inhibitors: Therapies and Ongoing Trials
por: Zhuang, Tony Zibo, et al.
Publicado: (2022)

Fat Loss in Patients with Metastatic Clear Cell Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors
por: Lee, Ji Hyun, et al.
Publicado: (2023)

Exceptional Response of Metastatic Chromophobe Renal Cell Carcinoma to Vascular Endothelial Growth Factor (VEGF) Inhibitors: Should Increased VEGF-C Expression Be Used to Guide Treatment?
por: Bruinius, Jacob W., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_gc0uun7kt4qcn94j555jhq1ksb